MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin — shares rocket higher
MacroGenics $MGNX has claimed success in their Phase III trial of their drug margetuximab for metastatic breast cancer, putting them on the path to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
